AUM Biosciences announced it has entered into a strategic collaboration agreement with Handok Inc. and CMG Pharmaceutical Co. Ltd. for the worldwide (ex-Korea) development, manufacturing and commercialisation rights of a highly specific, safe and efficacious Pan-TRK inhibitor. Financial terms of the agreement were not disclosed.

CHC2014 is completing a Phase I in Korea and has shown promising data to justify advancement to a tumor agnostic registrational program. CHC2014 has shown superior in-vivo anti-tumor activity compared to available treatment options. It has shown strong efficacy on solvent front and gatekeeper mutations addressing a unique solution to the current challenge in TRK Inhibitor market.

AUM “portfolio-model” strategy has made significant progress since its establishment through strategic collaborations and partnerships with leading academic institutions and pharmaceutical and biotech companies globally.